Lyell Immunopharma, Inc. Cash and Restricted Cash
Lyell Immunopharma, Inc. (LYEL) had Cash and Restricted Cash of $74.57 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $74.57M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $92.36M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $61.77M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $125.16M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $74.57M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $92.36M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $61.77M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $125.16M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $100.39M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $122.02M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $107.29M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $100.59M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $133.71M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $125.94M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $145.93M 10-K · filed 2026-03-12 |
| 2023-09-30 | $286.50M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $224.65M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $109.71M 10-Q · filed 2024-05-06 |
| 2022-12-31 | $123.83M 10-K · filed 2026-03-12 |
| 2022-09-30 | $116.59M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $206.02M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $222.88M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $294.29M 10-K · filed 2025-03-11 |
| 2021-09-30 | $393.97M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $564.91M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $244.84M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $140.87M 10-K · filed 2024-02-28 |
| 2020-09-30 | $134.88M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $246.42M 10-Q · filed 2021-08-12 |
| 2019-12-31 | $98.47M 10-K · filed 2023-02-28 |
| 2018-12-31 | $130.28M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |